Business Context and Reporting Period
Immix Biopharma, Inc. filed a Form 8-K dated March 10, 2023, and signed March 13, 2023. The company is an emerging growth company whose common stock trades on Nasdaq under the symbol IMMX.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity balances, or other operating or financial metrics.
Material Changes
Immix Biopharma stated that neither it nor any of its subsidiaries held cash deposits or securities at Silvergate Bank or Silicon Valley Bank.
Guidance, Risks, Contingencies, and Unusual Items
- The disclosure addresses potential exposure to the financial conditions of Silvergate Bank and Silicon Valley Bank and states that the company had no deposits or securities at either institution.
- No guidance, forecast, clinical update, financing transaction, contingency, or other material operating development is disclosed.
- The filing labels the disclosure under Item 1.01 but states that the information is furnished under Item 7.01 and is not deemed filed for purposes of Exchange Act Section 18 or incorporated by reference into other filings.
Facts for Investor Verification
- Verify the company's statement that neither it nor its subsidiaries held deposits or securities at Silvergate Bank or Silicon Valley Bank as of the relevant date.
- Review subsequent filings for any changes in banking relationships, liquidity, or financial condition.
- Note that this 8-K does not provide financial results or updated business guidance.